ArticleResearch square2026
Infiltrating Monocyte Fate Switch in Retinal Degeneration: From Early Pathology to Late Homeostasis.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The contribution of infiltrating monocyte-derived macrophages (MDMs) to neurodegeneration remains poorly understood. Using a CCR2-CreER-based lineage-tracing and ablation strategy in mouse models of retinal degeneration, we precisely tracked infiltrating monocytes and defined their functional evolution. We found that monocytes entering the degenerating retina rapidly downregulate CCR2 and progressively acquire microglial markers (e.g., TMEM119, P2RY12), adopt a ramified morphology, and acquire a transcriptional signature highly analogous to that of resident microglia-derived macrophages (MiDMs). While a subset of monocytes is cleared by activated microglia during the acute phase, others persist and integrate into the retinal macrophage niche, restoring myeloid homeostasis in later stages. Functionally, early monocyte infiltration is pathogenic; it amplifies neuroinflammation by inducing Müller cells to produce complement C3 and shifts microglial complement regulation toward the alternative pathway. Critically, selective ablation of monocytes during this acute phase attenuated C3 deposition, suppressed microglial activation, and preserved photoreceptors. Together, these findings reveal a temporally bifurcated role for infiltrating monocytes-as early drivers of complement-mediated pathology and later contributors to immune homeostasis-and identify monocyte infiltration as a stage-specific therapeutic target in neurodegenerative disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.